Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Oncotype DX Genomic Prostate Score® (GPSTM) results

What to expect

Each case of prostate cancer is unique. It's important for you and your doctor to explore the management option that addresses your situation and can most appropriately manage your health. The results from the Genomic Prostate Score® test can help you and your doctor better understand the likelihood of aggressive disease, so that together you can make decisions about how to treat your cancer.

 

How likely are you to benefit from treatment?

These short videos can help you prepare for your appointment with your doctor to review your Genomic Prostate Score® test and discuss next steps.

Clinically Low-Risk Prostate Cancer

 
Clinically Low-Risk Prostate Cancer

Clinically High-Risk Prostate Cancer

VIDEO COMING SOON


Clinically low-risk prostate cancer

Understand your test results

Deciding between active surveillance and immediate treatment for your prostate cancer is important. Your GPS result may help.

The GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.

Your personal GPS result

The bell curve illustrates where your GPS result falls in relation to the GPS results of other men in the same risk category.

 

Radical prostatectomy is an operation to remove the prostate gland and tissues surrounding it. All patients in the clinical validation studies were treated with radical prostatectomy.

Current and future risk

These results can predict both your chance of:

  1. Your cancer spreading (metastasis) and
  2. Dying from prostate cancer in the next 10 years

Personalized assessment for individualized treatment

Additional pathology endpoints (provided for men with Gleason score 3+4)

  1. Adverse Pathology predicts the probability your doctor would find more aggressive disease than expected from your biopsy. This helps your doctor know if you are a candidate for active surveillance or if immediate treatment is most appropriate for you.
  2. High-Grade Disease shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells.
  3. Non–Organ-Confined Disease indicates the likelihood that your cancer has already spread outside your prostate.

The GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.


Clinically high-risk prostate cancer

Understanding your GPS results

Deciding the most appropriate course of treatment for your prostate cancer is important. Your GPS result may help.

The GPS test measures prostate cancer gene levels to assess how aggressively your cancer will grow or spread. Since certain genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.

Your personal GPS result and risk category

Your score is based on a scale of 0-100. Your genomic risk will indicate how your tumor behaves and can help you and your doctor determine the most appropriate course of treatment.

Personalized assessment for individualized treatment

The GPS test provides a personalized assessment of how aggressive your prostate cancer is, helping you and your doctor discuss next steps with confidence.

Current and future risk

These results can predict both your chance of:

  1. Dying from prostate cancer and
  2. Your cancer spreading (metastasis) in the next 10 years

Learn how the GPS test helps individualize your treatment

Learn about the GPS testing process

In their own words: Stories  from patients with early-stage prostate cancer

See FAQs and videos  about the GPS test

89%
of GPS test patients have $0 financial responsibility*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Your cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how the GPS test will be covered.

94%
of GPS test patients have a financial responsibility of <$100*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all of the cost of the GPS test if they have not satisfied their deductible.

Learn about costs, coverage, and how Exact Sciences can help

 

 

*The numbers cited are based on historical patient billing data from 1/02/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about the GPS test coverage.